eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
6/2006
vol. 44
 
Share:
Share:
more
 
 
abstract:

Review paper
Efficacy and safety of TNF inhibitors – results of randomized controlled clinical trials

Anna Filipowicz-Sosnowska

Reumatologia 2006; 44, 6: 309–314
Online publish date: 2006/12/15
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
TNF inhibitors were first approved for treatment of active rheumatoid arthritis (RA) in 1998. Since that time, a series of multicentre, randomized controlled trials have been evaluated in early and established RA, in patients who had not been treated with methotrexate (Mtx) as well as in those who had an inadequate response to traditional disease modifying antirheumatic drugs (DMARD), including Mtx. In these trials approximately 6000 RA patients have participated. Clinical response to treatment and adverse effects of anti-TNF agents are discussed. The relative expense of TNF inhibitors makes their universal use impractical. The use of TNF inhibitors in the treatment of active RA should be considered when traditional DMARD, including combination therapy of DMARD, are not effective.
keywords:

rheumatoid arthritis, TNF-inhibitors, randomization, controlled clinical trials



Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe